MYELODYSPLASTIC SYNDROME

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This study tests two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant for people with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen helps patients live longer without the…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special stem cell transplant designed to reduce serious side effects like graft-versus-host disease. The trial compares Orca-T to standard stem cell transplants in 187…

This study tests a new radiation technique called total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant from a half-matched donor. The goal is to deliver higher radiation to cancer cells while protecting healthy organs, potentially reducing serious side…

This study compares two types of stem cell donors for children, teens, and young adults with high-risk leukemia or myelodysplastic syndrome (MDS). Participants receive a stem cell transplant from either a partially matched family donor or a fully matched unrelated donor. The goal…

This study tests a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is either related to prior cancer treatment or developed from other blood disorders. The goal is to fin…

This study tests whether giving two chemotherapy drugs (clofarabine and melphalan) before a donor stem cell transplant can help prevent leukemia from returning in patients whose cancer is in remission. The approach aims to kill any remaining cancer cells and stop the immune syste…

This study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works at controlling the disease. About 135 adults with these bloo…

This study tests an experimental drug called INCB057643, given alone or with another drug (ruxolitinib), in people with myelofibrosis and other advanced blood cancers. The main goal is to check safety and see if it can reduce spleen size, which is often enlarged in these conditio…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers who are…

This study tests whether adding special 'veto' cells to a stem cell transplant can help donor cells grow in the body without causing severe graft-versus-host disease (GVHD). It includes 16 people aged 12-75 with various blood cancers or bone marrow failure. The veto cells are tre…

This study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…

This study tests an oral drug called emavusertib (CA-4948) in adults with acute myeloid leukemia (AML) or a high-risk bone marrow disorder (MDS). The goal is to find the best dose and see if it can shrink or control the cancer. Participants must have already tried at least one st…

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…

This early-phase study tests a new therapy using donor immune cells trained to recognize four proteins found on AML and MDS cancer cells. The cells are given to patients at least 30 days after a stem cell transplant. The main goal is to find the safest dose and see if the cells c…

This early-phase study tests a new targeted therapy called PVEK, which delivers chemotherapy directly to cancer cells, combined with a standard chemo regimen (FLAG-Ida) for adults with newly diagnosed high-risk acute myeloid leukemia (AML) and other aggressive blood cancers. The …

This study tests a new drug (seclidemstat) combined with a standard drug (azacitidine) for people with myelodysplastic syndromes or chronic myelomonocytic leukemia. The goal is to find the best dose and see if the combo can shrink or control the cancer. About 24 adults with these…

This study tests whether adding epoetin alfa to lenalidomide helps people with myelodysplastic syndrome (MDS) and anemia better than lenalidomide alone. About 247 adults with low- or intermediate-risk MDS and low red blood cell counts took part. The main goal was to see if the co…

This study is for people newly diagnosed with a specific type of acute myeloid leukemia (AML) linked to prior cancer treatment or other bone marrow disorders. It tests whether adding the drug pomalidomide to standard chemotherapy can improve treatment results. About 50 adults wil…

This study is for people with high-risk acute leukemia or myelodysplastic syndrome (MDS). It tests a new way to prepare the body for a donor stem cell transplant by combining targeted radiation (TMLI) with two chemotherapy drugs. The goal is to find the safest dose that can kill …

This study tests a combination of two chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in about 50 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment, or with high-risk myelodysplastic syndrome (MDS). The goal is to see if the combinati…

This study tests whether adding venetoclax to a specific chemotherapy regimen before a donor stem cell transplant can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their cancer coming back. About 116 adults aged 18 to 70 with …

This study looks at whether a special health check-up for older adults (age 60+) can help doctors choose the safest stem cell transplant approach for blood cancers like leukemia or myelodysplastic syndrome. The check-up measures thinking, mobility, mood, and nutrition to tailor t…

This study tests an experimental drug called AZD6738 in adults with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease got worse after standard therapy. The main goal is to check the drug's safety and find the right dose. About 52 participants …

This study tests whether giving palifermin and leuprolide acetate (or degarelix) can help the immune system recover more quickly after a stem cell transplant from a donor. The trial includes 82 adults with blood cancers like leukemia or lymphoma. Researchers will measure CD4+ T c…

This study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults took part…

This early-stage trial tests a new drug called DR-18 in 20 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or persists after a stem cell transplant. DR-18 is designed to boost the body's immune system to fight the cancer. The main goals a…

This study tests a combination of two drugs, azacitidine and quizartinib, in 30 adults with certain blood cancers (MDS, MDS/MPN, CMML) that have specific gene mutations (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the cancer. This is not a c…

This study tests an experimental drug called HT-6184 in adults with a low-risk form of myelodysplastic syndrome (MDS) who have anemia (low red blood cells). The goal is to see if the drug can improve blood counts and reduce the need for transfusions. Participants take the drug fo…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus a chemotherapy drug (azacitidine) in people with myelodysplastic syndromes (MDS), a bone marrow disorder that can lead to leukemia. About 99 adults with MDS, either untreated or who have fai…

This early-stage trial tests the safety of combining two drugs, RAD001 and PKC412, in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to standard treatments. The goal is to find the highest safe dose of RAD001 when giv…

This study tests a combination of two drugs—guadecitabine and atezolizumab—in people with myelodysplastic syndrome or chronic myelomonocytic leukemia that has spread, returned, or not responded to prior treatment. The goal is to find the best dose and see if the combo can shrink …

This program gives patients with blood cancers like leukemia or myelodysplastic syndrome access to Orca-T, a cell therapy, when the commercial version made for them doesn't meet quality standards. The goal is to provide treatment when no other option is available. Participants ar…

This study tests two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia who haven't had treatment yet. The goal is to see how well the combination works at controlling the cancer and what side effects it causes. Abo…

This study tests a more precise radiation method (IMRT) for total body irradiation before stem cell transplant in 20 adults with acute leukemia or myelodysplastic syndrome. The goal is to reduce radiation to the lungs, lowering the risk of lung side effects while still preparing …

This phase 2 trial tests whether adding venetoclax to the drug ASTX727 works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related bone marrow cancers with too many immature cells. About 132 adults will receive either the combination or ASTX727 alon…

This early-phase trial tests whether giving a CMV vaccine to stem cell donors can boost the recipient's immunity after transplant. About 34 blood cancer patients receiving donor stem cells are involved. The goal is to prevent CMV viremia, a common and serious viral infection, wit…

This study is testing a new blood test called AlloHeme that looks at DNA to see if a patient's own cells are coming back after a bone marrow transplant. The goal is to find out if this test can predict a relapse of leukemia or myelodysplastic syndrome earlier than current methods…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…